Good news for NellOne Therapeutics Inc., the Knoxville area-based early stage biopharmaceutical company using a talented protein to plot a new future for regenerative medicine.
The company announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,752,663 with key composition claims to the company’s novel variant of the NELL1 protein, transforming the company’s ability to commercialize its pioneering science.
The utility patent is the first intellectual property owned by NellOne Therapeutics and joins a robust portfolio of 20 NELL1-based patents licensed from UT-Battelle, managing contractor for Oak Ridge National Laboratory.
“This patent solidifies NellOne’s place in the highly competitive field of regenerative medicine,” said Bill Malkes, NellOne’s Chief Executive Officer. “We are seeing yields of NV1 that are five times higher than the naturally occurring NELL1 protein, which will support significant cost reduction in future therapeutic uses. We are continuing to improve large-scale production and quality of the protein to further bring down costs and enhance efficacy to enable various formulations for different clinical scenarios.”